Abbott (ABT) to Launch Next-Generation XIENCE PRIME(TM) Drug Eluting Stent in International Markets
Abbott (NYSE: ABT) at International Market spread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease at the European Society of Cardiology Congress.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Press Releases
